Teva reports positive skin treatment drug results

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has reported optimistic outcomes for TEV-’408, an investigational anti-interleukin-15 monoclonal antibody, in an ongoing Section 1b, open-label research in adults with lively or steady non-segmental vitiligo (NSV). The Israeli firm will advance the antibody right into a Section 2b trial within the fourth quarter of 2026.

Teva collaborates on pores and skin illness remedy, releases targets

Teva to put off 250 in API division in Israel

Teva acquires Emalex Biosciences for as much as $900m

Teva sees decrease income and revenue in 2026

TEV-408 is designed to be administered by way of subcutaneous injection as soon as each 12 weeks. Teva reported within the research that sufferers confirmed enhancements in pores and skin pigmentation with lively or steady NSV. TEV-’408 was well-tolerated with no security alerts noticed to this point. Practically 75% of sufferers reported enchancment in facial vitiligo, with half reporting “a lot’ or “very a lot” improved, whereas 55% of sufferers reported enchancment in whole physique vitiligo.

Teva CEO Richard Francis mentioned, “TEV-’408 exemplifies the kind of revolutionary, Teva-discovered program we’re prioritizing as we proceed to advance and strengthen our immunology pipeline. Grounded in compelling biology and centered on significant unmet want, TEV-’408 displays our progress in our Pivot to Progress technique and our dedication to pursuing differentiated innovation for sufferers.”

Teva EVP world R&D and chief Medical officer Eric Hughes added, “Vitiligo can have an effect on way over the pores and skin. It could possibly form how folks see themselves, how they present up on this planet, and the arrogance they carry day-after-day. These encouraging knowledge strengthen our confidence within the IL-15 pathway and replicate the depth of Teva’s scientific experience. We’re excited by the potential of this program to supply a significant new choice for folks dwelling with vitiligo.”

Earlier this 12 months Teva introduced an settlement with Royalty Pharma to speed up growth of the Vitilago remedy. The settlement consists of cost by Royalty to Teva of as much as $500 million for funding the prices of growth, based mostly on the outcomes of the Section 2b research and an choice to pay an extra $425 million to fund a Section 3 trial. If the trials are efficiently accomplished and the product is launched, Teva can pay Royalty royalties on the worldwide gross sales of the drug.

Revealed by Globes, Israel enterprise information – en.globes.co.il – on July 7, 2026.

Source link